Affimed Stock Price, News & Analysis

Affimed has announced promising follow-up data for its AFM24 and atezolizumab combination therapy in heavily pretreated non-small cell lung cancer (NSCLC) patients. In the EGFR wild-type (EGFRwt) cohort, 4 out of 15 response-evaluable patients showed objective responses, with a median progression-free survival (PFS) of 5.9 months. Additionally, 8 patients achieved stable disease, resulting in a disease control rate of 71%. In the EGFR mutant (EGFRmut) cohort, 4 out of 13 response-evaluable patients also showed objective responses, with all responses ongoing. The combination therapy demonstrated a manageable safety profile, with mild to moderate side effects. The company is hosting a conference call to discuss these findings further. Recruitment for both cohorts is ongoing, with updates expected in the second half of 2024.

Affimed has received FDA Fast Track designation for its combination therapy of AFM24 with atezolizumab for advanced and metastatic EGFR wild-type non-small cell lung cancer (NSCLC). This designation is based on initial efficacy data from the ongoing AFM24-102 phase 1/2a study, which evaluates this combination in patients who have progressed after PD-(L)1 therapy and platinum-based chemotherapy. Fast Track status is intended to expedite the development of drugs that address serious conditions with unmet medical needs. Affimed will present updated data from the AFM24-102 study at the American Society of Clinical Oncology meeting on June 1, 2024.

Affimed, a clinical-stage immuno-oncology company, announced its 2024 Annual General Meeting of Shareholders. The meeting will take place on June 26, 2024, at 09:00 a.m. CET at De Brauw Blackstone Westbroek N.V. in Amsterdam, Netherlands. Key documents, including the notice and agenda of the Annual Meeting, can be found on Affimed's investor section on its website and the SEC's website.

Affimed has announced promising early results from its AFM24-102 study involving 15 evaluable patients with metastatic EGFR wild-type non-small cell lung cancer (NSCLC). These patients, pretreated with platinum doublet chemotherapy and checkpoint inhibitors, received a combination of AFM24 and atezolizumab, resulting in a disease control rate (DCR) of 73.3%. This included one complete response and three partial responses, with a median progression-free survival of 5.9 months. The study's data cut-off was March 18, 2024. These findings will be presented at the ASCO annual meeting on June 1, 2024. Affimed will also host a conference call/webcast the same day to discuss these results and other clinical data.

Affimed has announced the acceptance of an abstract showcasing preclinical data on its innate cell engager, AFM28, at the European Hematology Association (EHA) 2024 Congress. AFM28 targets CD123-positive cancer cells in acute myeloid leukemia (AML). Preclinical results demonstrated dose-dependent tumor growth control in a mouse model, leading to increased median lifespan compared to controls. Additionally, in an ex vivo bone marrow model, AFM28 combined with allogeneic NK cells effectively reduced CD123-expressing AML blasts and stem cells. This research, conducted in collaboration with Dr. Hind Medyouf's group, suggests that AFM28 could potentially eradicate residual disease in AML patients safely and effectively.